Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors

BACKGROUND: Immune checkpoint inhibitors (CIs) have revolutionized treatment of advanced melanoma, leading to an emerging population of long-term survivors. Survivors’ quality of life (QOL) and symptom burden are poorly understood. We set out to evaluate symptom burden and QOL in patients with advan...

Descripción completa

Detalles Bibliográficos
Autores principales: Mamoor, Maha, Postow, Michael A, Lavery, Jessica A, Baxi, Shrujal S, Khan, Niloufer, Mao, Jun J, Rogak, Lauren J, Sidlow, Robert, Thom, Bridgette, Wolchok, Jedd A, Korenstein, Deborah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7061889/
https://www.ncbi.nlm.nih.gov/pubmed/32152222
http://dx.doi.org/10.1136/jitc-2019-000260

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7061889/
https://www.ncbi.nlm.nih.gov/pubmed/32152222
http://dx.doi.org/10.1136/jitc-2019-000260

Ejemplares similares